BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35202726)

  • 1. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
    Reinhardt LS; Morás AM; Henn JG; Arantes PR; Ferro MB; Braganhol E; de Souza PO; de Oliveira Merib J; Borges GR; Dalanhol CS; de Barros Dias MCH; Nugent M; Moura DJ
    Int J Pharm; 2022 Apr; 617():121584. PubMed ID: 35202726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
    Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
    Janjua TI; Cao Y; Ahmed-Cox A; Raza A; Moniruzzaman M; Akhter DT; Fletcher NL; Kavallaris M; Thurecht KJ; Popat A
    J Control Release; 2023 May; 357():161-174. PubMed ID: 36965857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
    Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
    Michels LR; Fachel FNS; Schuh RS; Azambuja JH; de Souza PO; Gelsleichter NE; Lenz GS; Visioli F; Braganhol E; Teixeira HF
    J Control Release; 2023 Mar; 355():343-357. PubMed ID: 36731799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
    Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
    Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
    Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
    Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
    Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
    Zeng H; Yang Z; Xu N; Liu B; Fu Z; Lian C; Guo H
    Cell Death Dis; 2017 Jun; 8(6):e2885. PubMed ID: 28617438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
    Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
    Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
    [No Abstract]   [Full Text] [Related]  

  • 20. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
    Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
    Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.